Board: Mylan Failed To Prove Novo Nordisk Patents Are Obvious
(October 3, 2023, 2:26 PM EDT) -- ALEXANDRIA, Va. — The Patent Trial and Appeal Board denied institution of inter partes review (IPR) of several claims in two challenged Novo Nordisk A/S patents directed to a modified peptide hormone on Oct. 2....